News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Daiichi Sankyo Co Ltd. to Bid For Up to 20% of Ranbaxy Laboratories’s Zenotech Laboratories
January 20, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO/MUMBAI, Jan 19 (Reuters) - Japanese drugmaker Daiichi Sankyo will make an open offer for up to 20 percent of Zenotech Laboratories, a unit of India's Ranbaxy.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
Daiichi Sankyo
MORE ON THIS TOPIC
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
June 29, 2026
·
2 min read
·
Annalee Armstrong
